About: Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study
Creator	Park, Jin-Sung Chang, Min Park, Donghwi Kim, Ju-Hyun Hwang, Jong-Moon
Source	Medline; PMC
abstract	INTRODUCTION: In the current study, we evaluated factors that increase the coronavirus disease (COVID-19) patient death rate by analyzing the data from two cohort hospitals. In addition, we studied whether underlying neurological diseases are risk factors for death. METHODS: In this retrospective cohort study, we included 103 adult inpatients (aged ≥ 18 years). We evaluated differences in demographic data between surviving and non-surviving COVID-19 patients. RESULTS: In a multivariate logistic analysis, age and the presence of chronic lung disease and Alzheimer’s dementia (AD) were the only significant parameters for predicting COVID-19 non-survival (p < 0.05). However, hypertension, coronary vascular disease, dyslipidemia, chronic kidney disease, diabetes, and history of taking angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors, as well as nonsteroidal anti-inflammatory drugs (NSAIDs), were not significantly associated with the death of COVID-19 patients. The optimal cutoff value obtained from the maximum Youden index was 70 (sensitivity, 80.77%; specificity, 61.04%), and the odds ratio of non-survival increased 1.055 fold for every year of age. CONCLUSIONS: Clinicians should closely monitor and manage the symptoms of COVID-19 patients who are over the age of 70 years or have chronic lung disease or AD.
has issue date	2020-07-08(xsd:dateTime)
bibo:doi	10.1007/s10072-020-04541-z
bibo:pmid	32643133
has license	no-cc
sha1sum (hex)	29900b719fe99247e2f5db949090ab3ce9bc2a8a
schema:url	https://doi.org/10.1007/s10072-020-04541-z
resource representing a document's title	Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study
has PubMed Central identifier	PMC7342552
has PubMed identifier	32643133
schema:publication	Neurol Sci
resource representing a document's body	covid:29900b719fe99247e2f5db949090ab3ce9bc2a8a#body_text
is schema:about of	named entity 'diseases' named entity 'ADDITION' named entity '103' named entity 'INTRODUCTION' named entity 'HOSPITALS' named entity 'DATA' named entity 'current' named entity 'COVID-19' named entity 'data' named entity 'adult' named entity 'patients' named entity 'COVID-19' named entity 'patient' named entity 'death rate' named entity 'COVID' named entity 'Parkinson's disease' named entity 'chronic lung disease' named entity 'CKD' named entity 'Hypertension' named entity 'chronic medical' named entity 'Underlying diseases' named entity 'neurologist' named entity 'chronic lung disease' named entity 'anti-viral' named entity 'risk factors' named entity 'ROC' named entity 'chronic medical' named entity 'antipyretics' named entity 'South Korea' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'IBM' named entity 'severe acute respiratory syndrome' named entity 'Comorbidities' named entity 'COVID' named entity 'NSAIDs' named entity 'World Health Organization' named entity 'ARBs' named entity 'risk factors' named entity 'blood vessels' named entity 'sex ratio' named entity 'statistically significant' named entity 'comorbidities' named entity 'Korea' named entity 'sex ratio' named entity 'dyslipidemia' named entity 'SARS-CoV-2' named entity 'risk factors' named entity 'antipyretics' named entity 'regulatory T cells' named entity 'underlying diseases' named entity 'COVID' named entity 'death rate' named entity 'ROC' named entity 'ARBs' named entity 'risk factors' named entity 'chronic obstructive pulmonary disease' named entity 'neurologist' named entity 'hypertension' named entity 'SARS-CoV-2' named entity 'beta coefficient' named entity 'SARS' named entity 'Armonk' named entity 'risk factors' named entity 'risk factors' named entity 'immunosuppressant drugs' named entity 'stroke' named entity 'mortality rate' named entity 'older age' named entity 'KCDC' named entity 'dementia' named entity 'viral replication' named entity 'analyzing the data' named entity 'COVID' named entity 'Kyungpook National University' named entity 'ACE2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software